Cabrera-Pérez MÁ, Pérez ACM, Fernández CM

Language: Spanish
References: 15
Page:
PDF size: 358.46 Kb.

ABSTRACT

Introduction: The replacement of in vivo bioequivalence studies with in vitro dissolution assays, based on the Biopharmaceutical Classification System, has emerged as an important tool for demonstrating the therapeutic interchangeability of generic products.
Objective: Assess the chances and potentialities of the national pharmaceutical industry for the development and commercialization of effective and safe generic medicines, based on the application of in vitro bioequivalence studies.
Methods: An analysis of the international and national regulations on in vitro bioequivalence was carried out. A new provisional biopharmaceutical classification system was proposed and its application to the classification of oral solid forms of the 2019 Basic Chart of Medicines of Cuba was demonstrated.
Results: The analysis of the national regulation on in vitro bioequivalence and its comparison with the international regulatory show that since 2007 the regulatory one in Cuba has not been updated, which allows the demonstration of therapeutic interchangeability for drugs with high permeability and low solubility. Similarly, there is limited application of this regulation. The proposed consensus method for predicting permeability adequately classifies more than 95% of human permeability and allows for better interim biopharmaceutical classification. The model identified that more than 66% of the drugs included in oral formulations of immediate release of the Basic Chart of Medicines could be exempted from bioequivalence studies in humans and demonstrate their interchangeability through in vitro dissolution assays.
Conclusions: The Cuban pharmaceutical industry has the capacity and possibility to promote the development of interchangeable generics, with the application of in vitro bioequivalence studies, at a lower cost, which makes it possible to register and market them in the most demanding markets.

REFERENCES

1. Asociación Española de Medicamentos Genéricos. La industria farmacéutica demedicamentos genéricos en España frente a la pandemia de la Covid-19: Alservicio de los ciudadanos y del Sistema Nacional de Salud. España: AESEG; 2020[acceso 18/12/2021]. Disponible en:https://www.actasanitaria.com/documentos/informe-sobre-la-industria-demedicamentos-genericos-en-espana-frente-a-la-covid-19_1511858_102.html

2. WHO. Multisource (generic) pharmaceutical products: guidelines onregistration requirements to establish interchangeability. Annex 6, WHOTechnical Report Series, No 1003. Geneva: WHO; 2017 [acceso 18/12/2021]. p.18-236. Disponible en:https://digicollections.net/medicinedocs/documents/s23245en/s23245en.pdf

3. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for abiopharmaceutic drug classification: the correlation of in vitro drug productdissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20. DOI:10.1023/a:1016212804288

4. Cook JA, Davit B, Polli JE. Impact of Biopharmaceutics Classification System-Based Biowaivers. Mol Pharm. 2010;7(5):1539-44. DOI: 10.1021/mp1001747

5. CDER/FDA. Guidance for industry: Waiver of In Vivo Bioavailability andBioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based ona Biopharmaceutics Classification System. Florida: FDA; 2017 [acceso20/12/2021]. Disponible en: https://n9.cl/s9f7w

6. EMA. EMA/CHMP: Guidelines on the investigation of Bioequivalence. London:EMA; 2010 [acceso 20/12/2021]. Disponible en:https://www.ema.europa.eu/en/documents/scientific-guideline/guidelineinvestigation-bioequivalence-rev1_en.pdf

7. CHMP/ICH. The International Council for Harmonisation of TechnicalRequirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline.Biopharmaceutics classification system-based biowaivers M9. Amsterdam: EMA;2019 [acceso 20/12/2021]. Disponible en: https://www.ema.europa.eu/en/ichm9-biopharmaceutics-classification-system-based-biowaivers

8. Sánchez González CA. Experiencia Reguladora Cubana en Calidad yBioequivalencia para la Intercambiabilidad Terapéutica de MedicamentosGenéricos. Acta Farm Bonaer. 2006;25(3):468-73.

9. Miranda-Pérez de Alejo C, Aceituno Álvarez A, Mendes Lima Santos G,Fernández Cervera M, Jung-Cook H, Cabrera-Pérez MÁ. Policy of MultisourceDrug Products in Latin America: Opportunities and Challenges on the Applicationof Bioequivalence In Vitro Assays. Ther Innov Regul Sci. 2021 Jan 29;55(1):65-81.DOI: 10.1007/s43441-020-00191-7

10. Cabrera-Pérez MÁ, Pham-The H, Cervera MF, Hernández-Armengol R,Miranda-Pérez de Alejo C, Brito-Ferrer Y. Integrating theoretical andexperimental permeability estimations for provisional biopharmaceuticalclassification: Application to the WHO essential medicines. Biopharm DrugDispos. 2018;39(7):354-68. DOI: 10.1002/bdd.2152

11. Miranda-Pérez de Alejo C, Fernández-Cervera M, Reyes-Naranjo M, Cabrera-Pérez MA. Aplicación del Sistema de Clasificación Biofarmacéutica al CuadroBásico de Medicamentos de Cuba: ¿bioequivalencia in vivo o disolución in vitro?Rev OFIL·ILAPHAR. 2020 [acceso 20/12/2021];54830(4):1-10. Disponible en:https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2020000400007

12. Miranda C, Aceituno A, Fernández M, Mendes G, Rodríguez Y, Llauró V, et al.ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9):Toward Harmonization in Latin American Countries. Pharmaceutics. 2021 Mar10;13(3):363. DOI: 10.3390/pharmaceutics13030363

13. CECMED. Regulación 18-07: Requerimientos para estudios deBiodisponibilidad y Bioequivalencia. La Habana: CECMED; 2007.

14. CECMED. Regulación 41/2005: Requerimientos de la Demostración deIntercambiabilidad Terapéutica para el Registro de los Productos FarmacéuticosMultiorigen. La Habana: CECMED; 2005.

15. CECMED. Regulación No. 48 / 2007. Requisitos para aplicar y/o diseñar unensayo de disolución en cápsulas y tabletas de liberación inmediata. La Habana:CECMED; 2007.